This work investigates preparation by extrusion of microcellular antimicrobial polylactide (PLA) with an additive, the latter comprising 1% potassium aluminum sulfate dodecahydrate (ALUM), and 3% or 5% of a mixture of sodium hydrogen carbonate and sodium dihydrogen phosphate (1:1). Study was made as to the properties of the materials, their hydrolysis, release profiles, and antimicrobial properties in comparison with the pure polymer. Measuring the molecular weight of samples by gel permeation chromatography revealed that, during thermal processing, the molecular weight of the PLA prepared with additives mentiond above had reduced by approximately 43%. A mechanical test confirmed a decline in mechanical properties after processing as compared with the pure PLA. Release of the antimicrobial compound and the subsequent antimicrobial activity against Staphylococcus aureus and Escherichia coli was evaluated according to ISO 22196:2007. The release of ALUM from the microcellular specimens took place in two steps. During the first 10 days, the rate of release was extremely high in contrast with the remaining period.However, the release rate of the nonporous sample was seen to equal less than 1% in the first 10 days, a phenomenon probably arising through its less active surface.

: This study explores the feasibility of modifying the surface liquid spraying method to prepare porous bioscaffolds intended for wound dressing applications. For this purpose, gentamicin sulfate was loaded into polylactide-polyvinyl alcohol bioscaffolds as a highly soluble (hygroscopic) model drug for in vitro release study. Moreover, the influence of inorganic salts including NaCl (10 g/L) and KMnO4 (0.4 mg/L), and post-thermal treatment (T) (80 °C for 2 min) on the properties of the bioscaffolds were studied. The bioscaffolds were characterized by scanning electron microscopy, Fourier Transform infrared spectroscopy, and differential scanning calorimetry. In addition, other properties including porosity, swelling degree, water vapor transmission rate, entrapment efficiency, and the release of gentamicin sulfate were investigated. Results showed that high concentrations of NaCl (10 g/L) in the aqueous phase led to an increase of around 68% in the initial burst release due to the increase in porosity. In fact, porosity increased from 68.1 ± 1.2 to 94.1 ± 1.5. Moreover, the thermal treatment of the Polylactide-polyvinyl alcohol/NaCl (PLA-PVA/NaCl) bioscaffolds above glass transition temperature (Tg) reduced the initial burst release by approximately 11% and prolonged the release of the drug. These results suggest that thermal treatment of polymer above Tg can be an efficient approach for a sustained release.

No abstract

Despite the clinical benefits that chemotherapeutics has had on the treatment of breast cancer, drug resistance remains one of the main obstacles to curative cancer therapy. Nanomedicines allow therapeutics to be more targeted and effective, resulting in enhanced treatment success, reduced side effects, and the possibility of minimising drug resistance by the co-delivery of therapeutic agents. Porous silicon nanoparticles (pSiNPs) have been established as efficient vectors for drug delivery. Their high surface area makes them an ideal carrier for the administration of multiple therapeutics, providing the means to apply multiple attacks to the tumour. Moreover, immobilising targeting ligands on the pSiNP surface helps direct them selectively to cancer cells, thereby reducing harm to normal tissues. Here, we engineered breast cancer-targeted pSiNPs co-loaded with an anticancer drug and gold nanoclusters (AuNCs). AuNCs have the capacity to induce hyperthermia when exposed to a radiofrequency field. Using monolayer and 3D cell cultures, we demonstrate that the cell-killing efficacy of combined hyperthermia and chemotherapy via targeted pSiNPs is 1.5-fold higher than applying monotherapy and 3.5-fold higher compared to using a nontargeted system with combined therapeutics. The results not only demonstrate targeted pSiNPs as a successful nanocarrier for combination therapy but also confirm it as a versatile platform with the potential to be used for personalised medicine.